Clinical-Stage Companies / Deciphera

Deciphera

Pre-Approval PRO BETA

Total Trials

Phase 3

Phase 2

Recruiting

184

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Gastrointestinal Stromal Tumors Healthy Participants GIST Non-Small Cell Lung Cancer Advanced Solid Tumor

Clinical Trials (21)

NCT05059262 Phase 3 ACTIVE NOT RECRUITING

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Started: 10/14/2021

NCT03673501 Phase 3 ACTIVE NOT RECRUITING

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Started: 2/8/2019

NCT05734105 Phase 3 ACTIVE NOT RECRUITING

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Started: 12/13/2023

NCT03353753 Phase 3 COMPLETED

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

Started: 2/27/2018

NCT06619561 Phase 2 RECRUITING

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Started: 11/21/2024

NCT07539090 Phase 1 RECRUITING

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Started: 6/5/2026

NCT05957367 Phase 1 RECRUITING

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Started: 9/28/2023

NCT06966024 Phase 1 RECRUITING

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Started: 8/27/2025

NCT06630234 Phase 1 RECRUITING

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Started: 12/10/2024

NCT04892017 Phase 1 TERMINATED

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Started: 6/15/2021

NCT06287463 Phase 1 TERMINATED

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Started: 5/14/2024

NCT07158411 Phase 1 COMPLETED

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

Started: 11/20/2025

NCT07158398 Phase 1 COMPLETED

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Started: 10/31/2025

NCT03069469 Phase 1 ACTIVE NOT RECRUITING

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Started: 2/16/2017

NCT03717415 Phase 1 TERMINATED

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Started: 1/2/2019

NCT03601897 Phase 1 TERMINATED

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Started: 10/25/2018

NCT04530981 Phase 1 COMPLETED

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Started: 9/22/2021

NCT02571036 Phase 1 COMPLETED

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Started: 11/1/2015

NCT05080621 Phase 1 WITHDRAWN

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Started: 11/1/2021

NCT02228811 Phase 1 TERMINATED

A Study of DCC-2701 in Participants With Advanced Solid Tumors

Started: 6/1/2014

NCT00827138 Phase 1 COMPLETED

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

Started: 3/1/2009

Drug Candidates

Vimseltinib Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) Inlexisertib Ripretinib DCC-2812 DCC-3084 DCC-3009 Rebastinib DCC-2618 DCC-2701 tablet

Activity Status: Active

Last Trial Started: 6/5/2026

Last Trial Ended: 3/30/2026

Trials (12 months): 4

Completed Trials: 6

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.